Inadequate prophylactic effect of low-molecular weight heparin in critically ill COVID-19 patients
暂无分享,去创建一个
A. Larsson | S. Rubertsson | S. B. Anderberg | R. Frithiof | H. Andersson | M. Hultström | N. Lubenow | M. Lipcsey | M. Lipcsey | M. von Seth | K. Stattin | S. Bülow Anderberg | A. Gradin | E. Pontén | Sten Rubertsson | Anders Larsson | M. V. Seth
[1] M. Schenker,et al. Ability of Thromboelastography to Detect Hypercoagulability: A Systematic Review and Meta-Analysis. , 2020 .
[2] Matthieu Legrand,et al. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation , 2020, Intensive Care Medicine.
[3] P. Navalesi,et al. COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure , 2020, Thrombosis and Haemostasis.
[4] L. Menicanti,et al. The procoagulant pattern of patients with COVID‐19 acute respiratory distress syndrome , 2020, Journal of Thrombosis and Haemostasis.
[5] G. Grasselli,et al. Hypercoagulability of COVID‐19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis , 2020, Journal of Thrombosis and Haemostasis.
[6] D. Gommers,et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19 , 2020, Thrombosis Research.
[7] K. Hashimoto,et al. Nervous system involvement after infection with COVID-19 and other coronaviruses , 2020, Brain, Behavior, and Immunity.
[8] Dengju Li,et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy , 2020, Journal of Thrombosis and Haemostasis.
[9] A. Falanga,et al. ISTH interim guidance on recognition and management of coagulopathy in COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.
[10] Yuanliang Xie,et al. COVID-19 Complicated by Acute Pulmonary Embolism , 2020, Radiology. Cardiothoracic imaging.
[11] K. Yuen,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.
[12] Runsheng Wang,et al. Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study , 2020, American journal of respiratory and critical care medicine.
[13] Dengju Li,et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.
[14] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[15] Brown Wesley,et al. The Ability of Thromboelastography to Detect Hypercoagulability: A Systematic Review & Meta-Analysis. , 2019, Journal of orthopaedic trauma.
[16] H. Krumholz,et al. PULMONARY EMBOLISM HOSPITALIZATIONS AND USE OF INFERIOR VENA CAVAL FILTERS IN OLDER ADULTS: NATIONAL STUDY OF MEDICARE BENEFICIARIES , 2019, Journal of the American College of Cardiology.
[17] J. Dias,et al. New-Generation Thromboelastography: Comprehensive Evaluation of Citrated and Heparinized Blood Sample Storage Effect on Clot-Forming Variables. , 2017, Archives of pathology & laboratory medicine.
[18] M. Prasarn,et al. Can Thrombelastography Predict Venous Thromboembolic Events in Patients With Severe Extremity Trauma? , 2016, Journal of orthopaedic trauma.
[19] Matthew Wei,et al. The Anti-Factor Xa Range For Low Molecular Weight Heparin Thromboprophylaxis , 2015, Hematology reports.
[20] T. Baglin,et al. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.
[21] G. Guyatt,et al. Dalteparin versus unfractionated heparin in critically ill patients. , 2011, The New England journal of medicine.
[22] Peter Bauer,et al. SAPS 3—From evaluation of the patient to evaluation of the intensive care unit. Part 2: Development of a prognostic model for hospital mortality at ICU admission , 2005, Intensive Care Medicine.